Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05815082RecruitingPhase 3
ctDNA-guided chemo after liver surgery for colon cancer
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
Guangzhou, GuangdongAges 18–75 - NCT05819008Recruiting
Online brain testing for people with neurological conditions
This trial studies how well a remote, online memory and thinking assessment works for people with neurological disorders or injuries. You may be invited if you can do the computer-based testing and speak Swedish.
UmeåAges 18 years+ - NCT05835570Recruiting
PET scan using an integrin marker to find cancer
This trial uses a special PET/CT scan that targets a protein on some cancer cells to help detect and evaluate malignant tumors. It may help doctors better map tumors before any cancer treatment starts.
Wuhan, HubeiAges 18–85 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Aurora, ColoradoAges 1–39 - NCT05844865Recruiting
GI cancer study using a lab tumor model from your surgery
This study uses a special lab model made from tumor tissue taken during a planned standard cancer surgery. It tests how well the lab model can represent your cancer, which may help researchers improve future treatments.
Orange, CaliforniaAges 18 years+ - NCT05857800Recruiting
Studying how lung tumor treatment affects the tumor environment
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
ShanghaiAges 18 years+ - NCT05858424Recruiting
Day hospital program to improve young cancer survivors’ well-being
This study tests a structured “end-of-treatment” day hospital program to improve quality of life for adolescents and young adults after cancer treatment. You may be offered follow-up and supportive care soon after finishing treatment to help you feel better physically and emotionally.
LyonAges 15–25 - NCT05859659Recruiting
Hope HOPE study for glioma using pathology and MRI
This study looks at glioma (a type of brain tumor) and uses brain tissue testing, MRI scans, and related measurements to better understand the disease. You may benefit by being closely assessed with MRI and study follow-up, though it’s not necessarily testing a new medicine based on the listed criteria.
Beijing, Beijing MunicipalityAges 18–90 - NCT05862259Recruiting
Immunotherapy as first treatment for advanced stage IV cancers
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05865730RecruitingPhase 2
Oncobax immune treatment for advanced lung and kidney cancers
This trial tests Oncobax®-AK, an immune-based treatment, in people with advanced (stage IV) non-squamous lung cancer or clear cell kidney cancer. It seeks to see if the treatment can help cancer respond better and whether it is safe for patients who meet specific immune and health requirements.
MonsAges 18 years+ - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT05870423RecruitingPhase 1
Testing PARP inhibitors with peptide radiation for NET
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
Rotterdam, South HollandAges 18 years+ - NCT05871164Recruiting
Long-term study of radiofrequency treatment for pancreatic tumors
This study follows adults over time who are treated for a pancreatic tumor using ultrasound-guided radiofrequency through a thin needle. It aims to understand what happens after treatment and how patients do, so future care can improve.
ToulonAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05873231Recruiting
Gut microbiome study for diarrhea after anti-cancer treatment
This trial looks at how changes in the gut (microbiome) relate to diarrhea that can happen after starting anti-cancer therapy. It may help doctors better predict and manage treatment-related diarrhea.
GrazAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT05882370RecruitingPhase 2
Immunotherapy plus TIPS for liver cancer with blocked portal vein
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
Guangzhou, GuangdongAges 18–75 - NCT05882292RecruitingPhase 2
Study of a c-MET drug for advanced solid tumors
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
Seoul, SeoulAges 19 years+ - NCT05885009Recruiting
Liquid biopsy test to guide treatment in metastatic prostate cancer
This study looks at using a simple blood test (liquid biopsy) to read tumor DNA and understand how it could affect treatment decisions. It is for adults with metastatic prostate cancer who are about to start, are receiving, or recently finished treatment.
BarcelonaAges 18 years+ - NCT05894369Recruiting
Testing how the tumor environment affects pre-op chemo plus immunotherapy
This study looks at people with esophageal squamous cell carcinoma to see how changes in the “tumor neighborhood” may affect how well treatment works before surgery. If you’re eligible, you would receive chemotherapy plus immunotherapy as neoadjuvant (before-surgery) treatment.
Wuhan, HubeiAges 18–80 - NCT05896865Recruiting
Personalized breast cancer radiation based on tumor biology
This trial studies whether adjusting radiation dose using how the tumor behaves can improve outcomes for people with locally advanced breast cancer that has spread to certain nearby lymph nodes. It may help deliver the right radiation intensity while avoiding unnecessary exposure.
SeoulAges 19 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.